Primary Immunodeficiency in Kuwait

Kuwait National Primary Immunodeficiency Registry (KNPIDR)

• Background/Rationale: Epidemiological data about Primary Immunodeficiency Disorders (PIDD) in Kuwait is needed to better understand peculiarities and to compare them with other regions and ethnicity.
• Study hypothesis: PIDD is relatively common in Kuwait compared to populations from different geographic areas. The distribution of PIDD in Kuwait is different from other geographic areas with more severe forms being more frequent.
• Brief inclusion and exclusion criteria of study participants: PIDD patients presented at different clinics/hospital in Kuwait. Patients with secondary immunodeficiencies (drug induced, virus induced, and immunodeficiency associated with metabolic disorders... ect), will be excluded
• Estimated sample size of the study: All patients who were registered in KNPIDR since 2004 will be included in the study along with the new patients who will be recruited during the study period.

• Primary objectives:

  • Determine the prevalence and frequency of different PIDD in Kuwait
  • Identify clinical presentation patterns for PIDD in Kuwait
  • Identify natural history of PIDD in Kuwait
  • Help to asses epidemiology of PIDD in Kuwait
  • Determine particularities about PIDD affecting the population in Kuwait
  • Determine the health impact of PIDD in Kuwait
  • Development of strategies to improve the care and the quality of life of patients with PIDD

Study Overview

• Status: Completed
• Conditions: Primary Immune Deficiency Disorder

• Study Type: Observational
• Enrollment (Actual): 314

Contacts and Locations

Study Locations

• Kuwait
  • Kuwait, Kuwait
    • Pediatric Deprtmemt, Alsabah hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: ADULT; OLDER_ADULT; CHILD
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

PIDD patients in Kuwait

Description

Inclusion Criteria:

• PIDD patients presented at different clinics/hospital in Kuwait
• Exclusion Criteria: Patients with secondary immunodeficiencies (drug induced, virus induced, and immunodeficiency associated with metabolic disorders... ect)

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Number of Participants With Different Epidemiological Features	15 years
Number of Overall and New Cases of PID Per 100,000 Kuwaitis	15 years

Collaborators and Investigators

• Sponsor: Kuwait Society for Allergy and Clinical Immunology

Study record dates

Study Major Dates

• Study Start (ACTUAL): July 16, 2018
• Primary Completion (ACTUAL): May 1, 2019
• Study Completion (ACTUAL): May 1, 2019

Study Registration Dates

• First Submitted: July 30, 2018
• First Submitted That Met QC Criteria: August 3, 2018
• First Posted (ACTUAL): August 7, 2018

Study Record Updates

• Last Update Posted (ACTUAL): September 9, 2019
• Last Update Submitted That Met QC Criteria: September 5, 2019
• Last Verified: September 1, 2019

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Immune System Diseases; Genetic Diseases, Inborn; Immunologic Deficiency Syndromes; Primary Immunodeficiency Diseases
• Other Study ID Numbers: IIR - K W T - 0 0 2 0 7 1

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No